What is osteoarthritis (OA)?

Osteoarthritis is often referred to as a degenerative joint disease, which usually develops slowly over time. It is a very common disease, typically associated with joint pain. For example, 6% of adults 30 years old or older have frequent knee pain.¹^,2

With osteoarthritis, cartilage in the joint begins to break down and the amount of hyaluronic acid within the synovial fluid in the joint decreases, causing the fluid to become thinner and less functional.^3,4 The break down of cartilage and the loss of hyaluronic acid in synovial fluid contributes to pain, inflammation, swelling, and problems with moving your joint.^3-5

Osteoarthritis is one of the most common afflictions of the knee,³ but it’s a condition you can take charge of, work through, and overcome its symptoms.

Normal cartilage: Provides a smooth surface, allowing bones to move easily across each other.
Synovial fluid: Lubricates and provides shock absorption during activity due to a high concentration of hyaluronic acid.
Normal bone: Provides strength and support for the body’s tissues.

Eroded cartilage: If completely worn away, bones may scrape painfully against each other.
OA synovial fluid: The degeneration associated with osteoarthritis leads to reduced production of hyaluronic acid, and, presence of hyaluronic acid of poor quality.
OA bone: Bony spur growths (called osteophytes).

Summary of Indications for Use

DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.

DUROLANE (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.

Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within three months of the procedure.

You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.

Risks can include transient pain, swelling and/or stiffness at the injection site. Full prescribing information can be found in product labeling.

DUROLANE, Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. NASHA is a registered trademark of Nestlé Skin Health S.A.

Patient information leaflet available here.

© 2019 Bioventus LLC.

^{*First introduced in the European Union in 2001.}

To learn more about DUROLANE or for contact information, please select your location to continue.

Cookie Law

Our website uses cookies, some of which are essential for this site to operate correctly and have already been set. For more information on managing, blocking or deleting cookies within your browser please refer to the references within our Privacy Policy. By using our site you accept the terms of our Privacy policy.

Settings